市場調査レポート

商品コード

1083574

重症喘息市場 - 市場の洞察、疫学、市場予測：2032年

Severe Asthma - Market Insights, Epidemiology, and Market Forecast-2032

出版日: 2022年06月01日 | 発行: DelveInsight

| ページ情報: 英文 190 Pages | 納期: 1～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 7,500 1,165,950円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Site License)

USD 15,000 2,331,900円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。ご利用人数の制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Global License)

USD 22,500 3,497,850円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.46円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

主要7ヶ国における重症喘息の市場規模は、2021年に60億7,600万米ドルになりました。

当レポートでは、主要7ヶ国における重症喘息市場について調査し、市場の概要とともに、現在の治療法、新薬開発動向、2019～2032年の市場規模予測、および医療のアンメットニーズなどを提供しています。

List of Tables

Table 1: Summary of Severe Asthma, Market, Epidemiology, and Key Events (2019-2032)
Table 2: Key Events
Table 3: Classification of Asthma Severity
Table 4: Biomarker Tests Recommended For Asthma Phenotyping
Table 5: Diagnosed Prevalent Cases of Asthma in the 7MM, in Thousands (2019-2032)
Table 6: Diagnosed Prevalent cases of Asthma in the US, in Thousands (2019-2032)
Table 7: Severity-specific Diagnosed Prevalent Cases of Asthma in the US, in Thousands (2019-2032)
Table 8: Type-specific Diagnosed Prevalent Cases of Severe Asthma in the US, in Thousands (2019-2032)
Table 9: Diagnosed Prevalent cases of Asthma in Germany, in Thousands (2019-2032)
Table 10: Severity-specific Diagnosed Prevalent Cases of Asthma in Germany, in Thousands (2019-2032)
Table 11: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Germany, in Thousands (2019-2032)
Table 12: Diagnosed Prevalent cases of Asthma in France, in Thousands (2019-2032)
Table 13: Severity-specific Diagnosed Prevalent Cases of Asthma in France, in Thousands (2019-2032)
Table 14: Type-specific Diagnosed Prevalent Cases of Severe Asthma in France, in Thousands (2019-2032)
Table 15: Diagnosed Prevalent cases of Asthma in Italy, in Thousands (2019-2032)
Table 16: Severity-specific Diagnosed Prevalent Cases of Asthma in Italy, in Thousands (2019-2032)
Table 17: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Italy, in Thousands (2019-2032)
Table 18: Diagnosed Prevalent cases of Asthma in Spain, in Thousands (2019-2032)
Table 19: Severity-specific Diagnosed Prevalent Cases of Asthma in Spain, in Thousands (2019-2032)
Table 20: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Spain, in Thousands (2019-2032)
Table 21: Diagnosed Prevalent cases of Asthma in the UK, in Thousands (2019-2032)
Table 22: Severity-specific Diagnosed Prevalent Cases of Asthma in the UK, in Thousands (2019-2032)
Table 23: Type-specific Diagnosed Prevalent Cases of Severe Asthma in the UK, in Thousands (2019-2032)
Table 24: Diagnosed Prevalent cases of Asthma in Japan, in Thousands (2019-2032)
Table 25: Severity-specific Diagnosed Prevalent Cases of Asthma in Japan, in Thousands (2019-2032)
Table 26: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Japan, in Thousands (2019-2032)
Table 27: Comparison of Marketed Drugs (1)
Table 28: Comparison of Marketed Drugs (2)
Table 29: Cinqair (reslizumab), Clinical Trial Description, 2022
Table 30: Fasenra (benralizumab), Clinical Trial Description, 2022
Table 31: Nucala (mepolizumab), Clinical Trial Description, 2022
Table 32: Xolair (omalizumab), Clinical Trial Description, 2022
Table 33: Tezspire (Tezepelumab), Clinical Trial Description, 2022
Table 34: Dosage of Dupixent in Adult and Pediatric Patients 12 Years and Older with Asthma
Table 35: Dosage of Dupixent in Pediatric Patients 6 to 11 Years of Age with Asthma
Table 36: Dupixent (Dupilumab), Clinical Trial Description, 2022
Table 37: Comparison of Emerging Drugs Under Development
Table 38: GSK3511294 (Depemokimab), Clinical Trial Description, 2022
Table 39: PT027, Clinical Trial Description, 2022
Table 40: PT010, Clinical Trial Description, 2022
Table 41: MRx-4DP0004, Clinical Trial Description, 2022
Table 42: Masitinib, Clinical Trial Description, 2022
Table 43: CSJ117 (Ecleralimab), Clinical Trial Description, 2022
Table 44: Tozorakimab/ MEDI3506, Clinical Trial Description, 2022
Table 45: MTPS9579A (RG6173), Clinical Trial Description, 2022
Table 46: Rilzabrutinib, Clinical Trial Description, 2022
Table 47: AZD5718, Clinical Trial Description, 2022
Table 48: AVTX-002, Clinical Trial Description, 2022
Table 49: CBP-201 , Clinical Trial Description, 2022
Table 50: PRS-060/AZD1402, Clinical Trial Description, 2022
Table 51: Market Size of Severe Asthma in the 7MM in USD Million (2019-2032)
Table 52: Market Size of Severe Asthma by Therapies in the 7MM in USD Million (2019-2032)
Table 53: Key Market Forecast Assumptions for Tezepelumab
Table 54: Key Market Forecast Assumptions for GSK3511294
Table 55: Key Market Forecast Assumptions for PT027
Table 56: Key Market Forecast Assumptions for PT010
Table 57: Market Size of Severe Asthma in the United States, in USD Million (2019-2032)
Table 58: Market Size of Severe Asthma by Therapies in the United States, in USD Million (2019-2032)
Table 59: Market Size of Severe Asthma in the EU-5, in USD Million (2019-2032)
Table 60: Market Size of Severe Asthma by Therapies, in the EU-5, in USD Million (2019-2032)
Table 61: Market size of Severe Asthma in Germany, in USD Million (2019-2032)
Table 62: Market Size of Severe Asthma by Therapies in Germany, in USD Million (2019-2032)
Table 63: Market size of Severe Asthma in France, in USD Million (2019-2032)
Table 64: Market Size of Severe Asthma by Therapies in France, in USD Million (2019-2032)
Table 65: Market size of Severe Asthma in Italy, in USD Million (2019-2032)
Table 66: Market Size of Severe Asthma by Therapies in Italy, in USD Million (2019-2032)
Table 67: Market size of Severe Asthma in Spain, in USD Million (2019-2032)
Table 68: Market Size of Severe Asthma by Therapies in Spain, in USD Million (2019-2032)
Table 69: Market size of Severe Asthma in the UK, in USD Million (2019-2032)
Table 70: Market Size of Severe Asthma by Therapies in the UK, in USD Million (2019-2032)
Table 71: Market Size of Severe Asthma in Japan, in USD Million (2019-2032)
Table 72: Market Size of Severe Asthma by Therapies in Japan, in USD Million (2019-2032)

List of Figures

Figure 1: Classification Based on Treatment
Figure 2: Type 2 Airway Inflammation in Severe Asthma
Figure 3: Airway Remodeling in Asthma
Figure 4: Potential Interactions in the Setting of Severe Asthma Between Eosinophils and Fibroblasts Involving Transforming Growth Factor
Figure 5: Diagnosis and Treatment Algorithm
Figure 6: Molecular Targets of current and Future Biological Therapies of Severe Type 2 Asthma
Figure 7: Total Diagnosed Prevalent Cases of Asthma in the 7MM, in Thousands (2019-2032)
Figure 8: Total Diagnosed Prevalent cases of Asthma in the US, in Thousands (2019-2032)
Figure 9: Severity-specific Diagnosed Prevalent Cases of Asthma in the US, in Thousands (2019-2032)
Figure 10: Type-specific Diagnosed Prevalent Cases of Severe Asthma in the US, in Thousands (2019-2032)
Figure 11: Diagnosed Prevalent cases of Asthma in Germany, in Thousands (2019-2032)
Figure 12: Severity-specific Diagnosed Prevalent Cases of Asthma in Germany, in Thousands (2019-2032)
Figure 13: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Germany, in Thousands (2019-2032)
Figure 14: Diagnosed Prevalent cases of Asthma in France, in Thousands (2019-2032)
Figure 15: Severity-specific Diagnosed Prevalent Cases of Asthma in France, in Thousands (2019-2032)
Figure 16: Type-specific Diagnosed Prevalent Cases of Severe Asthma in France, in Thousands (2019-2032)
Figure 17: Diagnosed Prevalent cases of Asthma in Italy, in Thousands (2019-2032)
Figure 18: Severity-specific Diagnosed Prevalent Cases of Asthma in Italy, in Thousands (2019-2032)
Figure 19: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Italy, in Thousands (2019-2032)
Figure 20: Diagnosed Prevalent cases of Asthma in Spain, in Thousands (2019-2032)
Figure 21: Severity-specific Diagnosed Prevalent Cases of Asthma in Spain, in Thousands (2019-2032)
Figure 22: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Spain, in Thousands (2019-2032)
Figure 23: Diagnosed Prevalent cases of Asthma in the UK, in Thousands (2019-2032)
Figure 24: Severity-specific Diagnosed Prevalent Cases of Asthma in the UK, in Thousands (2019-2032)
Figure 25: Type-specific Diagnosed Prevalent Cases of Severe Asthma in the UK, in Thousands (2019-2032)
Figure 26: Diagnosed Prevalent cases of Asthma in Japan, in Thousands (2019-2032)
Figure 27: Severity-specific Diagnosed Prevalent Cases of Asthma in Japan, in Thousands (2019-2032)
Figure 28: Type-specific Diagnosed Prevalent Cases of Severe Asthma in Japan, in Thousands (2019-2032)
Figure 29: Patient Journey
Figure 30: Market Size of Severe Asthma in the 7MM, in USD Million (2019-2032)
Figure 31: Market Size of Severe Asthma by Therapies in the 7MM, in USD Million (2019-2032)
Figure 32: Market Size of Severe Asthma in the United States, in USD Million (2019-2032)
Figure 33: Market Size of Severe Asthma by Therapies in the United States, in USD Million (2019-2032)
Figure 34: Market Size of Severe Asthma in the EU-5, in USD Million (2019-2032)
Figure 35: Market Size of Severe Asthma by Therapies, in the EU-5, in USD Million (2019-2032)
Figure 36: Market size of Severe Asthma in Germany, in USD Million (2019-2032)
Figure 37: Market Size of Severe Asthma by Therapies in Germany, in USD Million (2019-2032)
Figure 38: Market size of Severe Asthma in France, in USD Million (2019-2032)
Figure 39: Market Size of Severe Asthma by Therapies in France, in USD Million (2019-2032)
Figure 40: Market size of Severe Asthma in Italy, in USD Million (2019-2032)
Figure 41: Market Size of Severe Asthma by Therapies in Italy, in USD Million (2019-2032)
Figure 42: Market size of Severe Asthma in Spain, in USD Million (2019-2032)
Figure 43: Market Size of Severe Asthma by Therapies in Spain, in USD Million (2019-2032)
Figure 44: Market size of Severe Asthma in the UK, in USD Million (2019-2032)
Figure 45: Market Size of Severe Asthma by Therapies in the UK, in USD Million (2019-2032)
Figure 46: Market Size of Severe Asthma in Japan, in USD Million (2019-2032)
Figure 47: Market Size of Severe Asthma by Therapies in Japan, in USD Million (2019-2032)
Figure 48: Market Drivers
Figure 49: Market Barriers
Figure 50: SWOT Analysis
Figure 51: Unmet Needs

Product Code: DIMI1088

DelveInsight's, 'Severe Asthma - Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Severe Asthma market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted 7MM Severe Asthma market size from 2019 to 2032. The Report also covers current Severe Asthma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019-2032

Severe Asthma Disease Understanding and Treatment Algorithm

Severe Asthma Overview

Asthma is the most common chronic respiratory illness worldwide. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), leading to variable and excessive airway narrowing.

It is a heterogeneous disease characterized by reversible bronchial obstruction with recurrent wheezing and airflow obstruction as its hallmark. Other features associated with asthma, such as epithelial sloughing, mucous hypersecretion, bronchial hyper-responsiveness, and mucosal edema, are variable and usually depend on the age of onset, associated comorbidities, laboratory abnormalities, and reversibility of airflow obstruction.

The characteristic symptoms of asthma include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate. These symptoms typically worsen at night and after exposure to triggers, such as environmental allergens, upper respiratory tract infections, tobacco, cold air, and exercise.

NAEPP/EPR guidelines broadly classify asthma into intermittent or persistent. Persistent asthma is further sub-divided based on severity into mild, moderate, and severe.

NIH Guidelines for diagnosis and treatment of asthma characterize severe persistent asthma by symptoms that tend to be continual, cause limitations in physical activity, and are generally associated with frequent and severe exacerbations. Most individuals with severe asthma have frequent nighttime symptoms and persistent airflow obstruction with a forced expiratory volume (FEV1) of less than 60% predicted before treatment. Based on the response to treatment, severe asthma is further classified into type-2 inflammation and non-type-2 inflammation. Type-2 inflammation includes allergic asthma and eosinophilic asthma (or e-asthma) while non-type-2 inflammation includes non-eosinophilic asthma.

Most people with asthma can manage their symptoms well with the usual medicines like a preventer inhaler and a reliever inhaler, but severe asthma is difficult to control the disease.

Severe Asthma Diagnosis

Severe asthma may be defined not only by difficult-to-control airway disease symptoms but also by the severity of abnormalities and measurements of pulmonary function. Careful physiologic characterizations of patients with well-defined severe asthma are lacking, making diagnosis difficult. In most cases, diagnosis depends on the symptoms and the response to treatment already being administered.

However, to establish a diagnosis of asthma, the clinician determines whether episodic symptoms of airflow obstruction or airway hyperresponsiveness are present and whether airflow obstruction is at least partially reversible, measured by spirometry. Reversibility is determined by an increase in FEV1 of >200 mL and 12% from baseline measure after inhalation of short-acting b2-agonist (SABA) (Lommatzsch & Virchow, 2014).

Continued in the report…..

Severe Asthma Treatment

Most asthma control medications focus on reducing airway inflammation and preventing the associated symptoms. The mainstay treatment for persistent asthma consists of inhaled corticosteroids. Quick-relief (reliever) or rescue medicines quickly ease symptoms that arise acutely Short-acting beta-agonists (SABAs) rapidly reduce airway bronchoconstriction and are recommended rescue medication for rapid symptom relief. Additional long-term controller medicines, such as long-acting beta 2 agonists (LABA), montelukast, or theophylline, are added if asthma is still uncontrolled. Oral corticosteroids can be added to treatment if patients are still experiencing symptoms and flare-ups. There are currently six approved monoclonal antibodies for add-on biological treatment of severe asthma. They include omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab for the treatment of severe asthma. At present, there is no approved therapy for severe non-eosinophilic asthma which is non-responsive to corticosteroid treatment also.

Continued in the report…..

Severe Asthma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of asthma, severity-specific diagnosed prevalent cases of asthma, and type-specific diagnosed prevalent cases of severe asthma, the scenario of Severe Asthma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings

Total diagnosed prevalent cases of asthma in the 7MM were found to be approximately 42,612,876 cases in adults and 11,602,740 cases in the pediatric population in the year 2021. These cases are expected to rise significantly by 2032.

The United States accounted for 5,189,648 and 20,868,845 diagnosed prevalent cases of pediatric and adult asthma, respectively in 2021.

In 2021, the total reported diagnosed prevalent cases (adult+pediatric) of asthma in EU-5 countries were 21,034,152 cases which are expected to rise significantly by 2032.

In 2021, the UK accounted for the highest number of asthma diagnosed prevalent cases (5,884,988), followed by France (4,117,330) among the EU-5 countries. In contrast, Spain accounts for the lowest number of cases of asthma diagnosed prevalent population in the EU-5.

As per DelveInsight analysis, in Japan, the intermittent, mild, moderate, and severe cases of asthma were observed to be 4,060,094, 854,757, 1,353,365, and 854,757 cases, respectively in 2021. The severity-specific cases are expected to change by 2032.

Severe Asthma Epidemiology

The epidemiology segment also provides the Severe Asthma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Severe Asthma Drug Chapters

The drug chapter segment of the Severe Asthma report encloses the detailed analysis of Severe Asthma marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Severe Asthma clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Severe Asthma Marketed Drugs

Cinqair (reslizumab): Teva Pharmaceutical

Cinqair injection is a humanized interleukin-5 antagonist monoclonal antibody for add-on maintenance treatment of adult patients with severe asthma and with an eosinophilic phenotype, developed by Teva Pharmaceuticals. Cinqair is for intravenous infusion only. It is not to be administered as an intravenous push or bolus. The recommended dosage regimen is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 min.

Fasenra (benralizumab): AstraZeneca

Fasenra (benralizumab) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous injection. Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM, developed by AstraZeneca. The IL-5 receptor is expressed on the surface of eosinophils and basophils. Benralizumab is produced in Chinese hamster ovary cells by recombinant DNA technology.

Products detail in the report…

List of products to be continued in the report…

Severe Asthma Emerging Drugs

GSK3511294 (Depemokimab): GlaxoSmithKline

GSK3511294 (depemokimab), which GlaxoSmithKline is developing to treat severe eosinophilic asthma, is a humanized anti-interleukin (IL)-5 monoclonal antibody. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. IL-5 are cytokines responsible for the proliferation, activation, and survival of eosinophils, thus making them a proven treatment target for severe asthma patients with higher levels of eosinophils.Depemokimab with an extended half-life and improved IL-5 affinity compared to other approved therapies is the first biologic to be administered subcutaneously once every 26 weeks. Currently, GlaxoSmithKline is conducting multiple Phase III trials to assess the safety and efficacy of depemokimab for the treatment of severe eosinophilic asthma.

PT027: AstraZeneca/Avillion

PT027, which AstraZeneca is developing in partnership with Avillion, is a fixed-dose combination of albuterol and budesonide. Albuterol, also known as salbutamol, is a short-acting beta2-agonist (SABA), while budesonide is an inhaled corticosteroid (ICS). It is a SABA/ICS fixed-dose rescue therapy for moderate to severe asthma being developed as a pressurized metered-dose inhaler (pMDI) using AstraZeneca's Aerosphere delivery technology. AstraZeneca has completed Phase III trials for PT027 and based on these results, the company plans to file for regulatory submission in the US in 2022

Products detail in the report…

List of products to be continued in the report…

Severe Asthma Market Outlook

The treatment aims to reduce the symptom burden (i.e., good symptom control while maintaining normal activity levels) and minimize the risk of adverse events such as exacerbations, fixed airflow limitation, and treatment side effects. Guideline-based management of asthma focuses on disease severity and choosing the appropriate medical therapy to control symptoms and reduce the risk of exacerbations.

In patients with mild persistent disease, low-dose Inhaled corticosteroids (ICS) decreases the risk of severe exacerbations leading to hospitalization and improving asthma control. When low-dose ICS is ineffective in controlling the disease, a combination of low-dose ICS with long-acting beta-agonist (LABA) maintenance is the recommended first-choice treatment, plus as-needed short-acting beta-agonists (SABA). Alternatively, the combination of low-dose ICS/LABA (formoterol) is to be used as single maintenance and reliever treatment.

Severe asthmatics require higher doses of inhalers and often require medications (anticholinergics) that relax the muscles around the airways, making it easier to breathe. Long-term usage of combination inhaled controller medications may not be sufficient for treating severe asthmatics, and long-term use of oral steroids carries the risk of increased side effects.

Several new therapeutic options for severe asthma are currently being emerged. The key players include GlaxoSmithKline, AstraZeneca, Bond Avillion, Novartis, 4D pharma, Roche, Pieris Pharma, AstraZeneca, Biosion, and others.

Key Findings

The market size of Severe Asthma in seven major markets was USD 6,076 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 5.09% for the study period (2019-2032).

The expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Severe Asthma.

The United States accounts for the largest market size for Severe Asthma, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Upcoming therapies such as GSK3511294 (Depemokimab) and PT010 have the potential to create a significant positive shift in the Severe Asthma market size.

Among the EU5 countries, the United Kingdom had the highest market size with USD 348 million in 2021.

The United States Market Outlook

This section provides the total Severe Asthma market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Severe Asthma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Severe Asthma market size and market size by therapies in Japan are provided.

Severe Asthma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Severe Asthma market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Severe Asthma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allow, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Severe Asthma Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Severe Asthma emerging therapies.

Reimbursement Scenario in Severe Asthma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Severe Asthma market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Severe Asthma, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.

Comprehensive insight has been provided into the Severe Asthma epidemiology and treatment.

Additionally, an all-inclusive account of both the current and emerging therapies for Severe Asthma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

A detailed review of the Severe Asthma market; historical and forecasted is included in the report, covering the 7MM drug outreach.

The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Severe Asthma market.

Report Highlights:

The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Severe Asthma market.

The companies and academics are working to assess challenges and seek opportunities that could influence Severe Asthma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Major players are involved in developing therapies for Severe Asthma. The launch of emerging therapies will significantly impact the Severe Asthma market.

Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Severe Asthma Report Insights

Patient Population
Therapeutic Approaches
Severe Asthma Pipeline Analysis
Severe Asthma Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Severe Asthma Report Key Strengths

11-Years Forecast
The 7MM Coverage
Severe Asthma Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Severe Asthma Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
SWOT analysis

Key Questions

Market Insights:

What was the Severe Asthma market share (%) distribution in 2019 and how it would look like in 2032?

What would be the Severe Asthma total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?

What are the key findings of the market across the 7MM and which country will have the largest Severe Asthma market size during the forecast period (2022-2032)?

At what CAGR, the Severe Asthma market is expected to grow at the 7MM level during the forecast period (2022-2032)?

What would be the Severe Asthma market outlook across the 7MM during the forecast period (2022-2032)?

What would be the Severe Asthma market growth till 2032 and what will be the resultant market size in the year 2032?

How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burdens, and unmet needs of Severe Asthma?

What is the historical Severe Asthma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?

What would be the forecasted patient pool of Severe Asthma at the 7MM level?

What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Severe Asthma?

Out of the above-mentioned countries, which country would have the highest population of Severe Asthma during the forecast period (2022-2032)?

At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the treatment of Severe Asthma along with the approved therapy?

What are the current treatment guidelines for the treatment of Severe Asthma in the US and Europe?

What are the Severe Asthma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?

How many companies are developing therapies for the treatment of Severe Asthma?

How many emerging therapies are in the mid-stage and late stages of development for the treatment of Severe Asthma?

What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to the Severe Asthma therapies?

What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Severe Asthma and their status?

What are the key designations that have been granted for the emerging therapies for Severe Asthma?

What is the 7MM historical and forecasted market for Severe Asthma?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving Severe Asthma.

To understand the future market competition in the Severe Asthma market and an Insightful review of the key market drivers and barriers.

Organize sales and marketing efforts by identifying the best opportunities for Severe Asthma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

Organize sales and marketing efforts by identifying the best opportunities for the Severe Asthma market.

To understand the future market competition in the Severe Asthma market.

1. Key Insights

2. Report Introduction

3. Severe Asthma Market Overview at a Glance

3.1. Market Share (%) Distribution of Severe Asthma by therapies in 2019
3.2. Market Share (%) Distribution of Severe Asthma by therapies in 2032

4. Severe Asthma Market: Future Perspective

5. Executive Summary of Severe Asthma

6. Key Events

7. Disease Background and Overview

7.1. Introduction of Severe Asthma
7.2. Classification of Severe Asthma
7.3. Signs and Symptoms of Severe Asthma
7.4. Causes of Severe Asthma
7.5. Pathophysiology of Severe Asthma
7.6. Diagnosis of Severe Asthma
7.7. Treatment and Management of Severe Asthma
7.8. Treatment Guidelines
- 7.8.1. International ERS/ATS guidelines on the Definition, Evaluation, and Treatment of Severe Asthma
- 7.8.2. Global Initiative for Asthma - Global Strategy for Asthma Management and Prevention 2022

8. Epidemiology and Patient Population

8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
- 8.3.1. Diagnosed Prevalent Cases of Asthma
- 8.3.2. Severity-specific cases of Asthma
- 8.3.3. Type-specific cases of Severe Asthma
8.4. Total Diagnosed Prevalent Cases of Asthma in the 7MM
8.5. The United States
- 8.5.1. Diagnosed prevalent cases of Asthma in the United States
- 8.5.2. Severity-specific Diagnosed Prevalent Cases of Asthma in the United States
- 8.5.3. Type-specific Diagnosed Prevalent Cases of Severe Asthma in the United States
8.6. EU-5 Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
- 8.6.1. Germany
  - 8.6.1.1. Diagnosed Prevalent Cases of Asthma in Germany
  - 8.6.1.2. Severity-specific Diagnosed Prevalent Cases of Asthma in Germany
  - 8.6.1.3. Type-specific Diagnosed Prevalent Cases of Severe Asthma in Germany
- 8.6.2. France
  - 8.6.2.1. Diagnosed Prevalent Cases of Asthma in France
  - 8.6.2.2. Severity-specific Diagnosed Prevalent Cases of Asthma in France
  - 8.6.2.3. Type-specific Diagnosed Prevalent Cases of Severe Asthma in France
- 8.6.3. Italy
  - 8.6.3.1. Diagnosed Prevalent Cases of Asthma in Italy
  - 8.6.3.2. Severity-specific Diagnosed Prevalent Cases of Asthma in Italy
  - 8.6.3.3. Type-specific Diagnosed Prevalent Cases of Severe Asthma in Italy
- 8.6.4. Spain
  - 8.6.4.1. Diagnosed Prevalent Cases of Asthma in Spain
  - 8.6.4.2. Severity-specific Diagnosed Prevalent Cases of Asthma in Spain
  - 8.6.4.3. Type-specific Diagnosed Prevalent Cases of Severe Asthma in Spain
- 8.6.5. The United Kingdom
  - 8.6.5.1. Diagnosed Prevalent Cases of Asthma in the United Kingdom
  - 8.6.5.2. Severity-specific Diagnosed Prevalent Cases of Asthma in the United Kingdom
  - 8.6.5.3. Type-specific Diagnosed Prevalent Cases of Severe Asthma in the United Kingdom
8.7. Japan
- 8.7.1. Diagnosed Prevalent Cases of Asthma in Japan
- 8.7.2. Severity-specific Diagnosed Prevalent Cases of Asthma in Japan
- 8.7.3. Type-specific Diagnosed Prevalent Cases of Severe Asthma in Japan

9. Patient Journey

10. Marketed Drugs

10.1. Key Competitors
10.2. Cinqair (reslizumab): Teva Pharmaceutical
- 10.2.1. Product Description
- 10.2.2. Regulatory Milestone
- 10.2.3. Other Development Activities
- 10.2.4. Clinical Trial Information
- 10.2.5. Safety and Efficacy
- 10.2.6. Product Profile
10.3. Fasenra (benralizumab): AstraZeneca
- 10.3.1. Product Description
- 10.3.2. Regulatory Milestone
- 10.3.3. Other Development Activities
- 10.3.4. Clinical Trial Information
- 10.3.5. Safety and Efficacy
- 10.3.6. Product Profile
10.4. Nucala (mepolizumab): GlaxoSmithKline (GSK)
- 10.4.1. Product Description
- 10.4.2. Regulatory Milestone
- 10.4.3. Other Development Activities
- 10.4.4. Clinical Trial Information
- 10.4.5. Safety and Efficacy
- 10.4.6. Product Profile
10.5. Xolair (omalizumab): Novartis
- 10.5.1. Product Description
- 10.5.2. Regulatory Milestone
- 10.5.3. Other Development Activities
- 10.5.4. Clinical Trial Information
- 10.5.5. Safety and Efficacy
- 10.5.6. Product Profile
10.6. Tezspire (tezepelumab): AstraZeneca
- 10.6.1. Product Description
- 10.6.2. Regulatory Milestone
- 10.6.3. Other Development Activities
- 10.6.4. Clinical Trial Information
- 10.6.5. Safety and Efficacy
- 10.6.6. Product Profile
10.7. Dupixent (dupilumab): Sanofi and Regeneron Pharmaceutical
- 10.7.1. Product Description
- 10.7.2. Regulatory Milestone
- 10.7.3. Clinical Trial Information
- 10.7.4. Safety and Efficacy
- 10.7.5. Product Profile

11. Emerging Drugs

11.1. Key Cross Competition
11.2. GSK3511294 (Depemokimab): GlaxoSmithKline
- 11.2.1. Product Description
- 11.2.2. Clinical Development
- 11.2.3. Clinical Trials Information
- 11.2.4. Safety and Efficacy
- 11.2.5. Product Profile
- 11.2.6. Analysts' Views
11.3. PT027: AstraZeneca/Avillion
- 11.3.1. Product Description
- 11.3.2. Other Developmental Activities
- 11.3.3. Clinical Development
- 11.3.4. Clinical Trials Information
- 11.3.5. Safety and Efficacy
- 11.3.6. Product Profile
- 11.3.7. Analysts' Views
11.4. PT010 (Breztri/Trixeo): AstraZeneca
- 11.4.1. Product Description
- 11.4.2. Clinical Development
- 11.4.3. Clinical Trials Information
- 11.4.4. Product Profile
- 11.4.5. Analysts' Views
11.5. MRx-4DP0004: 4D Pharma plc
- 11.5.1. Product Description
- 11.5.2. Clinical Development
- 11.5.3. Clinical Trials Information
- 11.5.4. Safety and Efficacy
- 11.5.5. Product Profile
- 11.5.6. Analysts' Views
11.6. Masitinib: AB Pharma
- 11.6.1. Product Description
- 11.6.2. Other Development
- 11.6.3. Clinical Development
- 11.6.4. Clinical Trials Information
- 11.6.5. Safety and Efficacy
- 11.6.6. Product Profile
- 11.6.7. Analysts' Views
11.7. CSJ117 (Ecleralimab): Novartis/Morphosys
- 11.7.1. Product Description
- 11.7.2. Other Development
- 11.7.3. Clinical Development
- 11.7.4. Clinical Trials Information
- 11.7.5. Safety and Efficacy
- 11.7.6. Product Profile
- 11.7.7. Analysts' Views
11.8. Tozorakimab/MEDI3506: AstraZeneca
- 11.8.1. Product Description
- 11.8.2. Clinical Development
- 11.8.3. Clinical Trials Information
- 11.8.4. Safety and Efficacy
- 11.8.5. Product Profile
- 11.8.6. Analysts' Views
11.9. MTPS9579A (RG6173): Roche
- 11.9.1. Product Description
- 11.9.2. Clinical Development
- 11.9.3. Clinical Trials Information
- 11.9.4. Safety and Efficacy
- 11.9.5. Product Profile
- 11.9.6. Analysts' Views
11.10. Rilzabrutinib: Sanofi
- 11.10.1. Product Description
- 11.10.2. Other Development
- 11.10.3. Clinical Development
- 11.10.4. Clinical Trials Information
- 11.10.5. Product Profile
- 11.10.6. Analysts' Views
11.11. AZD5718: AstraZeneca
- 11.11.1. Product Description
- 11.11.2. Clinical Development
- 11.11.3. Clinical Trials Information
- 11.11.4. Product Profile
- 11.11.5. Analysts' Views
11.12. AVTX-002: Avalo Therapeutics
- 11.12.1. Product Description
- 11.12.2. Clinical Development
- 11.12.3. Clinical Trials Information
- 11.12.4. Product Profile
- 11.12.5. Analysts' Views
11.13. CBP-201: Suzhou Connect Biopharmaceuticals
- 11.13.1. Product Description
- 11.13.2. Clinical Development
- 11.13.3. Clinical Trials Information
- 11.13.4. Product Profile
- 11.13.5. Analysts' Views
11.14. PRS-060/AZD1402: Pieris Pharma/AstraZeneca
- 11.14.1. Product Description
- 11.14.2. Other Development
- 11.14.3. Clinical Development
- 11.14.4. Clinical Trials Information
- 11.14.5. Safety and Efficacy
- 11.14.6. Product Profile
- 11.14.7. Analysts' Views
11.15. BSI-045B: Biosion
- 11.15.1. Product Description
- 11.15.2. Product Profile
- 11.15.3. Analysts' Views

12. Severe Asthma: Seven Major Market Analysis

12.1. Key Findings
12.2. Methodology of Severe Asthma Market
12.3. Market Size of Severe Asthma in the 7MM
12.4. Market Size of Severe Asthma by Therapies in the 7MM
12.5. Key Market Forecast Assumptions
12.6. Attribute Analysis
12.7. Market Outlook
12.8. The United States
- 12.8.1. Total Market Size of Severe Asthma in the US
- 12.8.2. Market Size of Severe Asthma by Therapies in the US
12.9. EU-5 Market Size
- 12.9.1. Germany
  - 12.9.1.1. The total market size of Severe Asthma in Germany
  - 12.9.1.2. Market Size of Severe Asthma by Therapies in Germany
- 12.9.2. France
  - 12.9.2.1. The total market size of Severe Asthma in France
  - 12.9.2.2. Market Size of Severe Asthma by Therapies in France
- 12.9.3. Italy
  - 12.9.3.1. The total market size of Severe Asthma in Italy
  - 12.9.3.2. Market Size of Severe Asthma by Therapies in Italy
- 12.9.4. Spain
  - 12.9.4.1. The total market size of Severe Asthma in Spain
  - 12.9.4.2. Market Size of Severe Asthma by Therapies in Spain
- 12.9.5. The United Kingdom
  - 12.9.5.1. The total market size of Severe Asthma in the UK
  - 12.9.5.2. Market Size of Severe Asthma by Therapies in the UK
12.10. Japan
- 12.10.1. Total Market Size of Severe Asthma in Japan
- 12.10.2. Market Size of Severe Asthma by Therapies in Japan

重症喘息市場 - 市場の洞察、疫学、市場予測：2032年

Severe Asthma - Market Insights, Epidemiology, and Market Forecast-2032

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 重症喘息市場の概要

第4章 重症喘息市場：将来の展望

第5章 重症喘息のエグゼクティブサマリー

第6章 主要なイベント

第7章 病気の背景と概要

第8章 疫学と患者人口

第9章 患者動向

第10章 市販薬

第11章 新薬

第12章 重症喘息：主要7ヶ国市場分析

第13章 主要なオピニオンリーダーの見解

第14章 市場促進要因

第15章 市場の障壁

第16章 SWOT分析

第17章 アンメットニーズ

第18章 償還と市場アクセス

第19章 付録

第20章 DelveInsightのサービス内容

第21章：免責事項

第22章 DelveInsightについて

List of Tables

List of Figures

Geography Covered:

Severe Asthma Disease Understanding and Treatment Algorithm

Severe Asthma Overview

Severe Asthma Diagnosis

Continued in the report…..

Severe Asthma Treatment

Continued in the report…..

Severe Asthma Epidemiology

Key Findings

Severe Asthma Epidemiology

Severe Asthma Drug Chapters

Severe Asthma Marketed Drugs

Cinqair (reslizumab): Teva Pharmaceutical

Fasenra (benralizumab): AstraZeneca

Products detail in the report…

List of products to be continued in the report…

Severe Asthma Emerging Drugs

GSK3511294 (Depemokimab): GlaxoSmithKline

PT027: AstraZeneca/Avillion

Products detail in the report…

List of products to be continued in the report…

Severe Asthma Market Outlook

Key Findings

The United States Market Outlook

EU-5 Market Outlook

Japan Market Outlook

Severe Asthma Drugs Uptake

Severe Asthma Development Activities

Pipeline Development Activities

Reimbursement Scenario in Severe Asthma

Competitive Intelligence Analysis

Scope of the Report:

Report Highlights:

Severe Asthma Report Insights

Severe Asthma Report Key Strengths

Severe Asthma Report Assessment

Key Questions

Market Insights:

Epidemiology Insights:

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

Reasons to buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Severe Asthma Market Overview at a Glance

4. Severe Asthma Market: Future Perspective

5. Executive Summary of Severe Asthma

6. Key Events

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Emerging Drugs

第1章重要な洞察

第2章レポートのイントロダクション

第3章重症喘息市場の概要

第4章重症喘息市場：将来の展望

第5章重症喘息のエグゼクティブサマリー

第6章主要なイベント

第7章病気の背景と概要

第8章疫学と患者人口

第9章患者動向

第10章市販薬

第11章新薬

第12章重症喘息：主要7ヶ国市場分析

第13章主要なオピニオンリーダーの見解

第14章市場促進要因

第15章市場の障壁

第17章アンメットニーズ

第18章償還と市場アクセス

第19章付録